Drug intelligence / Profile preview

MIC6479

Development stage: Preclinical
Lead developer: Micar Innovation
Modality: Small Molecules

Overview

MIC6479 is a small molecule therapeutic candidate currently in preclinical development by Micar Innovation for the treatment of pancreatic cancer. Developed using Micar Innovation's proprietary drug discovery platform, the compound is part of a pipeline focused on addressing high unmet medical needs in oncology and other therapeutic areas. While the specific molecular target of MIC6479 remains undisclosed by the developer, it is being advanced as a wholly-owned asset within their oncology portfolio.

Beyond the preview

Go deeper on MIC6479.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIC6479.

Explore the full profile